RxDoctor Payments Data

James Cicchiello, MD

General Practice · Louisville, KYNPI 1730144296

Payments from drug & device makers

$2,589in general payments, 2019–2025

Across 94 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$988
  • GSK$317
  • Amgen$265
  • Novo Nordisk$237
  • Novartis$189
  • Pfizer$162
  • plus $430 from 6 others

What the payments were for

  • Food & beverage$2,589100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,589 in reported general payments places this provider in the 90th percentile of 1,155 general practice providers in Kentucky.

See all general practice providers in Kentucky

Medicare billing

Part B allowed, 2024
$66,807
Medicare patients
164
Services billed
1,579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$121,944
Dupixent SyringeDupilumab15$58,760
JardianceEmpagliflozin37$35,877
JanuviaSitagliptin Phosphate21$34,109
XareltoRivaroxaban29$32,296
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$30,065
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$27,614
OzempicSemaglutide21$26,243
FarxigaDapagliflozin Propanediol22$21,773
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen602$12,297
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$9,531
PaxlovidNirmatrelvir/Ritonavir11$5,716
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$5,615
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,269
MovantikNaloxegol Oxalate12$4,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$162$127,661156 claims
Boehringer IngelheimJardiance$124$35,87737 claims
Johnson & JohnsonXarelto$988$32,29629 claims
GSKTrelegy Ellipta$317$27,61428 claims
Novo NordiskOzempic$237$26,24321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,155 general practice providers in Kentucky.

Other general practice in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →